SRPT: Sarepta Therapeutics Completes NDA Submission to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

New alert via PocketInfo for SRPT:

Sarepta Therapeutics Completes NDA Submission to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Press Releases: http://investorrelations.sareptatherapeutics.com/phoenix.zhtml?c=64231&p=irol-news&nyo=0
SEC Filings: http://investorrelations.sareptatherapeutics.com/phoenix.zhtml?c=64231&p=irol-sec
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8